Q-omics provides the consensus-scored ZNF496 profile across patient tissues and cancer cell-line models. ZNF496 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ZNF496 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, ZNF496 RNA expression shows 20,899 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where ZNF496 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF496 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF496 survival associations across molecular data types. ZNF496 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF496 RNA expression–survival associations across cancer types. High ZNF496 expression shows unfavorable associations in ACC, KIRP and THCA, but favorable associations in KIRC, BRCA and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ZNF496 RNA expression.
This table summarizes ZNF496 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF496. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF496 shows lower tumor expression in KICH and higher tumor expression in HNSC, KIRC, COAD, KIRP and CHOL. The HNSC box plot shows higher ZNF496 RNA expression in tumor versus normal tissue (log2 FC = +0.886, t-test p < 0.001).
This table shows molecular features associated with ZNF496 in patient tissues and cancer cell lines. In patient samples, ZNF496 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF496 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
